DOCSLIB.ORG

Table S4. Proteins in the First and Secondary Interactomes of Beta-Catenin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Table S4. Proteins in the first and secondary interactomes of beta-Catenin I. Genes/proteins in the first interactome of betaCatenin UniProtKB Genes in the UniProtKB Query Gene Entry Interactome Entry Protein Name CTNNB1 P35222 MUC1 P15941 Mucin-1 BTRC Q9Y297 F-box/WD repeat-containing protein 1A AR A0A0B4J1T2 Androgen receptor SMAD3 P84022 Mothers against decapentaplegic homolog 3 UBC P0CG48 Polyubiquitin-C PSEN1 P49768 Presenilin-1 NR5A2 O00482 Nuclear receptor subfamily 5 group A member 2 TRRAP Q9Y4A5 Transformation/transcription domain-associated protein AXIN1 O15169 Axin-1 HDAC1 Q13547 Histone deacetylase 1 GSK3B P49841 Glycogen synthase kinase-3 beta TCF4 P15884 Transcription factor 4 CUL1 Q13616 Cullin-1 RUVBL1 Q9Y265 RuvB-like 1 CTNNA1 P35221 Catenin alpha-1 CHD8 Q9HCK8 Chromodomain-helicase-DNA-binding protein 8 PTPRF P10586 Receptor-type tyrosine-protein phosphatase F PARD3 Q8TEW0 Partitioning defective 3 homolog AXIN2 Q9Y2T1 Axin-2 EGFR P00533 Epidermal growth factor receptor MEN1 O00255 Menin TCF7L2 Q9NQB0 Transcription factor 7-like 2 FBXW11 Q9UKB1 F-box/WD repeat-containing protein 11 CTNNBIP1 Q9NSA3 Beta-catenin-interacting protein 1 CDH5 P33151 Cadherin-5 APC P25054 Adenomatous polyposis coli protein SKP1 P63208 S-phase kinase-associated protein 1 CREBBP Q92793 CREB-binding protein CDH1 P12830 Cadherin-1 RUVBL2 X6R2L4 RuvB-like 2 ERBB2 P04626 Receptor tyrosine-protein kinase erbB-2 LEF1 Q9UJU2 Lymphoid enhancer-binding factor 1 BCL9 O00512 B-cell CLL/lymphoma 9 protein CDH3 P22223 Cadherin-3 TCF7 P36402 Transcription factor 7 CDH2 P19022 Cadherin-2 PITX2 Q99697 Pituitary homeobox 2 RBBP5 Q15291 Retinoblastoma-binding protein 5 APC2 O95996 Adenomatous polyposis coli protein 2 II. Genes/proteins in the Secondary Interactome of beta-Catenin (Genes interacting with the genes in the first interactome of beta-Catenin) UniProtKB Genes in the UniProtKB Query Gene Entry Interactome Entry Protein Name MUC1 P15941 SRC P12931 Proto-oncogene tyrosine-protein kinase Src EGFR P00533 Epidermal growth factor receptor CTNNB1 P35222 Catenin beta-1 UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa BTRC Q9Y297 OGT O15294 subunit HIVEP1 P15822 Zinc finger protein 40 C13orf34 B5LMG6 Aurora borealis NUDC Q9Y266 Nuclear migration protein nudC NFKB2 Q00653 Nuclear factor NF-kappa-B p100 subunit SKP1 P63208 S-phase kinase-associated protein 1 USP47 Q96K76 Ubiquitin carboxyl-terminal hydrolase 47 IKBKB J3KNS5 Inhibitor of nuclear factor kappa-B kinase subunit beta NFKB1 P19838 Nuclear factor NF-kappa-B p105 subunit APC P25054 Adenomatous polyposis coli protein HIVEP2 P31629 Transcription factor HIVEP2 CTNNB1 P35222 Catenin beta-1 CDC25A P30304 M-phase inducer phosphatase 1 ATF4 P18848 Cyclic AMP-dependent transcription factor ATF-4 MED20 Q9H944 Mediator of RNA polymerase II transcription subunit 20 CLPX O76031 ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial SMAD4 Q13485 Mothers against decapentaplegic homolog 4 CLSPN Q9HAW4 Claspin SNAI1 O95863 Zinc finger protein SNAI1 TUBGCP3 Q96CW5 Gamma-tubulin complex component 3 CDC34 P49427 Ubiquitin-conjugating enzyme E2 R1 NRD1 B1AKJ5 Nardilysin FBXW11 Q9UKB1 F-box/WD repeat-containing protein 11 PDCD4 Q53EL6 Programmed cell death protein 4 NFKBIA P25963 NF-kappa-B inhibitor alpha CUL1 Q13616 Cullin-1 AR A0A0B4J1T2 TGFB1I1 O43294 Transforming growth factor beta-1-induced transcript 1 protein PIAS2 A0A0A0MS92 E3 SUMO-protein ligase PIAS2 NCOA4 Q13772 Nuclear receptor coactivator 4 NCOA2 Q15596 Nuclear receptor coactivator 2 MDM2 J3KN53 E3 ubiquitin-protein ligase Mdm2 RB1 P06400 Retinoblastoma-associated protein EGFR P00533 Epidermal growth factor receptor KLK3 P07288 Prostate-specific antigen RNF14 Q9UBS8 E3 ubiquitin-protein ligase RNF14 RCHY1 Q96PM5 RING finger and CHY zinc finger domain-containing protein 1 EP300 Q09472 Histone acetyltransferase p300 SRC P12931 Proto-oncogene tyrosine-protein kinase Src STUB1 Q9UNE7 E3 ubiquitin-protein ligase CHIP HDAC1 Q13547 Histone deacetylase 1 TMPRSS2 O15393 Transmembrane protease serine 2 SMAD3 P84022 Mothers against decapentaplegic homolog 3 RNF4 P78317 E3 ubiquitin-protein ligase RNF4 SMARCA4 P51532 Transcription activator BRG1 UBC P0CG48 Polyubiquitin-C HSP90AA1 P07900 Heat shock protein HSP 90-alpha CREBBP Q92793 CREB-binding protein CTNNB1 P35222 Catenin beta-1 PA2G4 Q9UQ80 Proliferation-associated protein 2G4 SP1 P08047 Transcription factor Sp1 KAT5 Q92993 Histone acetyltransferase KAT5 NCOA3 Q9Y6Q9 Nuclear receptor coactivator 3 NCOA1 Q15788 Nuclear receptor coactivator 1 NCOR2 Q9Y618 Nuclear receptor corepressor 2 NCOR1 O75376 Nuclear receptor corepressor 1 STAT3 P40763 Signal transducer and activator of transcription 3 SMAD3 P84022 AR A0A0B4J1T2 Androgen receptor CTNNB1 P35222 Catenin beta-1 HDAC1 Q13547 Histone deacetylase 1 JUN P05412 Transcription factor AP-1 NEDD9 Q14511 Enhancer of filamentation 1 RUNX2 Q13950 Runt-related transcription factor 2 SKI P12755 Ski oncogene MAPK1 P28482 Mitogen-activated protein kinase 1 SMURF2 Q9HAU4 E3 ubiquitin-protein ligase SMURF2 KAT2B Q92831 Histone acetyltransferase KAT2B ZEB2 O60315 Zinc finger E-box-binding homeobox 2 SMAD2 Q15796 Mothers against decapentaplegic homolog 2 CREBBP Q92793 CREB-binding protein TFE3 P19532 Transcription factor E3 SP1 P08047 Transcription factor Sp1 PIN1 Q13526 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 SKIL P12757 Ski-like protein EP300 Q09472 Histone acetyltransferase p300 ZFYVE9 O95405 Zinc finger FYVE domain-containing protein 9 RNF111 Q6ZNA4 E3 ubiquitin-protein ligase Arkadia SMAD4 Q13485 Mothers against decapentaplegic homolog 4 SMURF1 Q9HCE7 E3 ubiquitin-protein ligase SMURF1 TRIM33 Q9UPN9 E3 ubiquitin-protein ligase TRIM33 UBC P0CG48 Polyubiquitin-C UBC P0CG48 ABCA1 O95477 ATP-binding cassette sub-family A member 1 ACTB P60709 Actin, cytoplasmic 1 APOBEC3G Q9HC16 DNA dC->dU-editing enzyme APOBEC-3G AR A0A0B4J1T2 Androgen receptor ARHGEF7 Q14155 Rho guanine nucleotide exchange factor 7 ATP1B1 P05026 Sodium/potassium-transporting ATPase subunit beta-1 ATXN3 D3VVP3 Ataxin 3 variant h AUP1 Q9Y679 Ancient ubiquitous protein 1 BECN1 Q14457 Beclin-1 BIRC6 Q9NR09 Baculoviral IAP repeat-containing protein 6 BMI1 P35226 Polycomb complex protein BMI-1 BRCA1 P38398 Breast cancer type 1 susceptibility protein BRCA2 P51587 Breast cancer type 2 susceptibility protein BRCC3 H9KVA9 Lys-63-specific deubiquitinase BRCC36 CCDC50 Q8IVM0 Coiled-coil domain-containing protein 50 CCT4 P50991 T-complex protein 1 subunit delta CDK9 P50750 Cyclin-dependent kinase 9 CDKN2A A0A0A0MRI0 Cyclin-dependent kinase inhibitor 2A COPS5 Q92905 COP9 signalosome complex subunit 5 CRKL P46109 Crk-like protein CXCR4 P61073 C-X-C chemokine receptor type 4 DAPK1 P53355 Death-associated protein kinase 1 DDX58 O95786 Probable ATP-dependent RNA helicase DDX58 DHX9 Q08211 ATP-dependent RNA helicase A DNTT P04053 DNA nucleotidylexotransferase E2F1 Q01094 Transcription factor E2F1 EIF3A Q14152 Eukaryotic translation initiation factor 3 subunit A EPN1 Q9Y6I3 Epsin-1 EPS15 P42566 Epidermal growth factor receptor substrate 15 ETS1 P14921 Protein C-ets-1 FAF1 Q9UNN5 FAS-associated factor 1 FAM175A Q6UWZ7 BRCA1-A complex subunit Abraxas FBP1 P09467 Fructose-1,6-bisphosphatase 1 FGFR1 P11362 Fibroblast growth factor receptor 1 FOXO1 Q12778 Forkhead box protein O1 FOXO4 P98177 Forkhead box protein O4 FTL P02792 Ferritin light chain FYN P06241 Tyrosine-protein kinase Fyn G6PD P11413 Glucose-6-phosphate 1-dehydrogenase GNAS Q5JWF2 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas GPI P06744 Glucose-6-phosphate isomerase H2AFX P16104 Histone H2AX HDAC1 Q13547 Histone deacetylase 1 HIST2H2BE Q16778 Histone H2B type 2-E HNRNPA3 P51991 Heterogeneous nuclear ribonucleoprotein A3 HNRNPH1 P31943 Heterogeneous nuclear ribonucleoprotein H HNRNPK P61978 Heterogeneous nuclear ribonucleoprotein K HSF2 Q03933 Heat shock factor protein 2 HTT P42858 Huntingtin IGHG1 A0A0A0MS08 Ig gamma-1 chain C region (Fragment) IKBKE Q14164 Inhibitor of nuclear factor kappa-B kinase subunit epsilon IKBKG Q9Y6K9 NF-kappa-B essential modulator INPP5D Q92835 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 IRAK1 P51617 Interleukin-1 receptor-associated kinase 1 ITCH Q96J02 E3 ubiquitin-protein ligase Itchy homolog JAK2 O60674 Tyrosine-protein kinase JAK2 JUN P05412 Transcription factor AP-1 KLF5 Q13887 Krueppel-like factor 5 KRT18 P05783 Keratin, type I cytoskeletal 18 L1CAM P32004 Neural cell adhesion molecule L1 LDHA P00338 L-lactate dehydrogenase A chain MAP3K1 Q13233 Mitogen-activated protein kinase kinase kinase 1 MAP3K5 Q99683 Mitogen-activated protein kinase kinase kinase 5 MAP3K7 O43318 Mitogen-activated protein kinase kinase kinase 7 MAVS Q7Z434 Mitochondrial antiviral-signaling protein MCL1 Q07820 Induced myeloid leukemia cell differentiation protein Mcl-1 MDC1 Q14676 Mediator of DNA damage checkpoint protein 1 MDM2 J3KN53 E3 ubiquitin-protein ligase Mdm2 MDM4 O15151 Protein Mdm4 MYC P01106 Myc proto-oncogene protein MYLIP Q8WY64 E3 ubiquitin-protein ligase MYLIP NCOA3 Q9Y6Q9 Nuclear receptor coactivator 3 NEDD4 P46934 E3 ubiquitin-protein ligase NEDD4 NEDD4L Q96PU5 E3 ubiquitin-protein ligase NEDD4-like NFE2L1 J9JIE5 Nuclear factor erythroid 2-related factor 1 NFE2L2 Q16236 Nuclear factor erythroid 2-related factor 2 NHLRC1 Q6VVB1 E3 ubiquitin-protein ligase NHLRC1 NTRK1 J3KP20 Tyrosine-protein kinase receptor OCLN Q16625 Occludin OTUD7B Q6GQQ9 OTU domain-containing protein 7B PARK2 O60260 E3 ubiquitin-protein ligase parkin PARP1 P09874 Poly [ADP-ribose]
Recommended publications
  • Thesis Template

    Thesis Template

    Functional and Structural Characterization Reveals Novel FBXW7 Biology by Tonny Chao Huang A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Medical Biophysics University of Toronto © Copyright by Tonny Chao Huang 2018 Functional and Structural Characterization Reveals Novel FBXW7 Biology Tonny Chao Huang Master of Science Department of Medical Biophysics University of Toronto 2018 Abstract This thesis aims to examine aspects of FBXW7 biology, a protein that is frequently mutated in a variety of cancers. The first part of this thesis describes the characterization of FBXW7 isoform and mutant substrate profiles using a proximity-dependent biotinylation assay. Isoform-specific substrates were validated, revealing the involvement of FBXW7 in the regulation of several protein complexes. Characterization of FBXW7 mutants also revealed site- and residue-specific consequences on the binding of substrates and, surprisingly, possible neo-substrates. In the second part of this thesis, we utilize high-throughput peptide binding assays and statistical modelling to discover novel features of the FBXW7-binding phosphodegron. In contrast to the canonical motif, a possible preference of FBXW7 for arginine residues at the +4 position was discovered. I then attempted to validate this feature in vivo and in vitro on a novel substrate discovered through BioID. ii Acknowledgments The past three years in the Department of Medical Biophysics have defied expectations. I not only had the opportunity to conduct my own independent research, but also to work with distinguished collaborators and to explore exciting complementary fields. I experienced the freedom to guide my own academic development, as well as to pursue my extracurricular interests.
  • Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”

    Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”

    Supplemental information to Mammadova-Bach et al., “Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinogenesis” Supplemental material and methods Cloning of the villin-LMα1 vector The plasmid pBS-villin-promoter containing the 3.5 Kb of the murine villin promoter, the first non coding exon, 5.5 kb of the first intron and 15 nucleotides of the second villin exon, was generated by S. Robine (Institut Curie, Paris, France). The EcoRI site in the multi cloning site was destroyed by fill in ligation with T4 polymerase according to the manufacturer`s instructions (New England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Site directed mutagenesis (GeneEditor in vitro Site-Directed Mutagenesis system, Promega, Charbonnières-les-Bains, France) was then used to introduce a BsiWI site before the start codon of the villin coding sequence using the 5’ phosphorylated primer: 5’CCTTCTCCTCTAGGCTCGCGTACGATGACGTCGGACTTGCGG3’. A double strand annealed oligonucleotide, 5’GGCCGGACGCGTGAATTCGTCGACGC3’ and 5’GGCCGCGTCGACGAATTCACGC GTCC3’ containing restriction site for MluI, EcoRI and SalI were inserted in the NotI site (present in the multi cloning site), generating the plasmid pBS-villin-promoter-MES. The SV40 polyA region of the pEGFP plasmid (Clontech, Ozyme, Saint Quentin Yvelines, France) was amplified by PCR using primers 5’GGCGCCTCTAGATCATAATCAGCCATA3’ and 5’GGCGCCCTTAAGATACATTGATGAGTT3’ before subcloning into the pGEMTeasy vector (Promega, Charbonnières-les-Bains, France). After EcoRI digestion, the SV40 polyA fragment was purified with the NucleoSpin Extract II kit (Machery-Nagel, Hoerdt, France) and then subcloned into the EcoRI site of the plasmid pBS-villin-promoter-MES. Site directed mutagenesis was used to introduce a BsiWI site (5’ phosphorylated AGCGCAGGGAGCGGCGGCCGTACGATGCGCGGCAGCGGCACG3’) before the initiation codon and a MluI site (5’ phosphorylated 1 CCCGGGCCTGAGCCCTAAACGCGTGCCAGCCTCTGCCCTTGG3’) after the stop codon in the full length cDNA coding for the mouse LMα1 in the pCIS vector (kindly provided by P.
  • Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin

    Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin

    Published OnlineFirst September 8, 2009; DOI: 10.1158/1541-7786.MCR-09-0033 Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin Jianmin Zhang,1 Young-Han Song,1 Brian W. Brannigan,1 Doke C.R. Wahrer,1 Taryn A. Schiripo,1 Patricia L. Harris,1 Sara M. Haserlat,1 Lindsey E. Ulkus,1 Kristen M. Shannon,1 Judy E. Garber,2 Matthew L. Freedman,3 Brian E. Henderson,4 Lee Zou,1 Dennis C. Sgroi,1 Daniel A. Haber,1 and Daphne W. Bell1 1Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts; 2Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; 3Department of Molecular Biology, Massachusetts General Hospital, Department of Genetics, Harvard Medical School, and Broad Institute for Biomedical Research, Boston, Massachusetts; and 4Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California Abstract mutation, was defective in its ability to mediate CHK1 Mutational inactivation of genes controlling the phosphorylation followingDNA damageand was unable to DNA-damage response contributes to cancer susceptibility rescue sensitivity to replicative stress in CLSPN-depleted within families and within the general population as well as cells. Taken together, these observations raise the to sporadic tumorigenesis. Claspin (CLSPN) encodes a possibility that CLSPN may encode a component of the recently recognized mediator protein essential for the ATR DNA-damage response pathway that is targeted by and CHK1-dependent checkpoint elicited by replicative mutations in human cancers, suggesting the need for larger stress or the presence of ssDNA. Here, we describe a study population-based studies to investigate whether CLSPN to determine whether mutational disruption of CLSPN variants contribute to cancer susceptibility.
  • List of Abbreviation

    List of Abbreviation

    Exploring and Potentiating Human Bone Marrow Derived Mesenchymal Stem Cells [hBMSCs] and Differentiated Islets for Effective Diabetes Therapy ABBREVIATION LIST OF ABBREVIATION AF555-Alexa Fluor 555 EBs- Embryoid bodies AGE- advanced glycosylation end-product EDTA- Ethylenediaminetetraacetic acid aPKC- Atypical protein kinase C EGF-Epidermal growth factor ANOVA-Analysis of variance EGFR- epidermal growth factor receptor Arx- Aristaless-related homeobox gene EL- Enicostemma littorale ATP- Adenosine triphosphate ELISA- Enzyme linked immunosorbent bHLH- Basic helix–loop–helix assay BM- Bone marrow EMT - epithelial–mesenchymal transition BMC- Bioactive molecules cocktail ESCs- Embryonic stem cells BMP-bone morphogenic protein FACS- Fluorescent activated cell sorter BSA- Bovine serum albumin FBS- Fetal Bovine Serum cAMP- Cyclic Adenosine monophosphate FDA- Food and Drug Administration CaCl2 –Calcium chloride FGF- Fibroblast growth factor CD-Cluster of differentiation FITC- Fluorescein isothiocyanate cDNA –Complementary DNA FOXO1-Forkhead box protein O1 ChIP-Chromatin immunoprecipitation FOXA2 - Forkhead box protein A2 CCl4- Carbon tetrachloride GAD- Glutamate decarboxylase CDK- Cyclin dependent kinase GATA4 -(GATA Binding Protein 4) CK-Cytokeratin GATA6- (GATA Binding Protein 6) CNS- Central Nervous System GCK- Glucokinase CPCSEA- Committee for the purpose of GFP- Green Fluorescent protein control and supervision of experiments on GLP-1- Glucagon-like peptide-1 animals GLUT- Glucose Transporter DAPI- 4’6’-diamidino-2-phenylindole GPx- Glutathione peroxidase Dihydrochloride GSH- Reduced glutathione DCFDA- 2',7' –dichlorofluorescin diacetate GSIS- Glucose-stimulated insulin secretion DM-Diabetes mellitus GTT- Glucose tolerance test DMEM- KO -Dulbecco’s Modified Eagle H & E- Hematoxylin and Eosin Media-Knock out hBMSCs: Human bone marrow-derived DMSO- Dimethyl Sulphoxide mesenchymal stem cell DTZ- Dithizone HGF- Hepatocyte Growth Factor Mitul Vakani.
  • ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes

    ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes

    OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes This article was published in the following Dove Press journal: OncoTargets and Therapy Rui-zhe Li1 Background: ACTL6A, a regulatory subunit of ATP-dependent chromatin-remodeling Yun-yun Li1,2 complexes SWI/SNF, has been identified as a central oncogenic driver in many tumor types. Hui Qin1 Materials and Methods: We used immunohistochemistry (IHC) to detect ACTL6A Shan-shan Li1 expression in esophageal squamous cell carcinoma (ESCC) tissues. Then, the effect of ACTL6A on proliferation and DNA synthesis was explored by using cell counting kit 8 1 Department of Pathology, School of (CCK8) and EdU retention assays. The potential oncogenic mechanism of ACTL6A in Basic Medical Sciences, Zhengzhou University and First Affiliated Hospital of ESCC cells was also analyzed by flow cytometry and Western blotting. We further estab­ Zhengzhou University, Zhengzhou, lished an ESCC xenograft mouse model to validate the in vitro results. Henan 450000, People’s Republic of China; 2Department of Stomatology, First Results: ACTL6A expression, localized in cancer cell nuclei, was markedly higher in ESCC Affiliated Hospital of Zhengzhou tissues than in the corresponding noncancerous tissues (P<0.001) and was positively asso­ University, Zhengzhou, Henan 450000, ciated with tumor size, histological differentiation, T stage and tumor-node-metastasis People’s Republic of China (TNM) stage. Kaplan–Meier analysis revealed that high ACTL6A expression was signifi­ cantly associated with poor overall survival (OS) (P = 0.008, HR= 2.562, 95% CI: 1.241–­ 5.289), and decision curve analysis (DCA) demonstrated that ACTL6A could increase the clinical prognostic efficiency of the original clinical prediction model.
  • A Pathogenic Ctbp1 Missense Mutation Causes Altered Cofactor Binding and Transcriptional Activity

    A Pathogenic Ctbp1 Missense Mutation Causes Altered Cofactor Binding and Transcriptional Activity

    neurogenetics (2019) 20:129–143 https://doi.org/10.1007/s10048-019-00578-1 ORIGINAL ARTICLE A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activity David B. Beck1 & T. Subramanian2 & S. Vijayalingam2 & Uthayashankar R. Ezekiel3 & Sandra Donkervoort4 & Michele L. Yang5 & Holly A. Dubbs6 & Xilma R. Ortiz-Gonzalez7 & Shenela Lakhani8 & Devorah Segal9 & Margaret Au10 & John M. Graham Jr10 & Sumit Verma11 & Darrel Waggoner12 & Marwan Shinawi13 & Carsten G. Bönnemann4 & Wendy K. Chung14 & G. Chinnadurai2 Received: 23 October 2018 /Revised: 18 March 2019 /Accepted: 9 April 2019 /Published online: 30 April 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract We previously reported a pathogenic de novo p.R342W mutation in the transcriptional corepressor CTBP1 in four independent patients with neurodevelopmental disabilities [1]. Here, we report the clinical phenotypes of seven additional individuals with the same recurrent de novo CTBP1 mutation. Within this cohort, we identified consistent CtBP1-related phenotypes of intellectual disability, ataxia, hypotonia, and tooth enamel defects present in most patients. The R342W mutation in CtBP1 is located within a region implicated in a high affinity-binding cleft for CtBP-interacting proteins. Unbiased proteomic analysis demonstrated reduced interaction of several chromatin-modifying factors with the CtBP1 W342 mutant. Genome-wide transcriptome analysis in human glioblastoma cell lines expressing -CtBP1 R342 (wt) or W342 mutation revealed changes in the expression profiles of genes controlling multiple cellular processes. Patient-derived dermal fibroblasts were found to be more sensitive to apoptosis during acute glucose deprivation compared to controls. Glucose deprivation strongly activated the BH3-only pro-apoptotic gene NOXA, suggesting a link between enhanced cell death and NOXA expression in patient fibroblasts.
  • Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd

    Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd

    Product List 2015 WE LIVE SERVICE Certificates quartett owns two productions sites that are certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list 2015 quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. First of all we would like to introduce ourselves to you. Founded as a family-run company in 1986, quartett ensures for more than a quarter of a century consistent quality of products. Service and support of our valued customers are our daily businesses. And we will continue! In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 and a second one in 2011 supported this decision. The company specialized its product profile in the field of manufacturing synthetic peptides for antibody production, peptides such as protease inhibitors, biochemical reagents and products for histology, cytology and immunohistology. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals, and private doctor offices.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Increased ACTL6A Occupancy Within Mswi/SNF Chromatin Remodelers

    Increased ACTL6A Occupancy Within Mswi/SNF Chromatin Remodelers

    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.22.435873; this version posted March 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Increased ACTL6A Occupancy Within mSWI/SNF Chromatin Remodelers Drives Human Squamous Cell Carcinoma Chiung-Ying Chang1,2,7, Zohar Shipony3,7, Ann Kuo1,2, Kyle M. Loh4,5, William J. Greenleaf3,6, Gerald R. Crabtree1,2,5* 1Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305, USA. 2Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA. 3Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA. 4Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. 5Department of Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA. 6Department of Applied Physics, Stanford University, Stanford, California 94305, USA. 7These authors contributed equally. *Corresponding author: Gerald R. Crabtree, [email protected] Summary Mammalian SWI/SNF (BAF) chromatin remodelers play dosage-sensitive roles in many human malignancies and neurologic disorders. The gene encoding the BAF subunit, ACTL6A, is amplified at an early stage in the development of squamous cell carcinomas (SCCs), but its oncogenic role remains unclear. Here we demonstrate that ACTL6A overexpression leads to its stoichiometric assembly into BAF complexes and drives its interaction and engagement with specific regulatory regions in the genome. In normal epithelial cells, ACTL6A was sub-stoichiometric to other BAF subunits. However, increased ACTL6A levels by ectopic expression or in SCC cells led to near-saturation of ACTL6A within BAF complexes.
  • A SARS-Cov-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

    A SARS-Cov-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

    A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing Supplementary Information Supplementary Discussion All SARS-CoV-2 protein and gene functions described in the subnetwork appendices, including the text below and the text found in the individual bait subnetworks, are based on the functions of homologous genes from other coronavirus species. These are mainly from SARS-CoV and MERS-CoV, but when available and applicable other related viruses were used to provide insight into function. The SARS-CoV-2 proteins and genes listed here were designed and researched based on the gene alignments provided by Chan et. al. 1 2020 .​ Though we are reasonably sure the genes here are well annotated, we want to note that not every ​ protein has been verified to be expressed or functional during SARS-CoV-2 infections, either in vitro or in vivo. ​ ​ In an effort to be as comprehensive and transparent as possible, we are reporting the sub-networks of these functionally unverified proteins along with the other SARS-CoV-2 proteins. In such cases, we have made notes within the text below, and on the corresponding subnetwork figures, and would advise that more caution be taken when examining these proteins and their molecular interactions. Due to practical limits in our sample preparation and data collection process, we were unable to generate data for proteins corresponding to Nsp3, Orf7b, and Nsp16. Therefore these three genes have been left out of the following literature review of the SARS-CoV-2 proteins and the protein-protein interactions (PPIs) identified in this study.
  • Identifying the Role of Wilms Tumor 1 Associated Protein in Cancer Prediction Using Integrative Genomic Analyses

    Identifying the Role of Wilms Tumor 1 Associated Protein in Cancer Prediction Using Integrative Genomic Analyses

    MOLECULAR MEDICINE REPORTS 14: 2823-2831, 2016 Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses LI‑SHENG WU1*, JIA-YI QIAN2*, MINGHAI WANG3* and HAIWEI YANG4 1Department of General Surgery, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001; 2Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029; 3Department of General Surgery, The First Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241002; 4Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China Received August 31, 2015; Accepted June 2, 2016 DOI: 10.3892/mmr.2016.5528 Abstract. The Wilms tumor suppressor, WT1 was first iden- regulatory factor 1, glucocorticoid receptor and peroxisome tified due to its essential role in the normal development of proliferator‑activated receptor γ transcription factor binding the human genitourinary system. Wilms tumor 1 associated sites were identified in the upstream (promoter) region of the protein (WTAP) was subsequently revealed to interact with human WTAP gene, suggesting that these transcription factors WT1 using yeast two‑hybrid screening. The present study may be involved in WTAP functions in tumor formation. identified 44 complete WTAP genes in the genomes of verte- brates, including fish, amphibians, birds and mammals. The Introduction vertebrate WTAP proteins clustered into the primate, rodent and teleost lineages using phylogenetic tree analysis. From The Wilms tumor suppressor gene WT1 was first identified 1,347 available SNPs in the human WTAP gene, 19 were due to its essential role in the normal development of the identified to cause missense mutations.
  • NICU Gene List Generator.Xlsx

    NICU Gene List Generator.Xlsx

    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2